Clinical Trial Update: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma [Phase 1]

View source ↗

Summary

A University of Pennsylvania-sponsored Phase 1 trial of tasquinimod for relapsed or refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Tasquinimod (tasquinimod)

Snippet

Sponsor: University of Pennsylvania | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED